Lipocine's LPCN 2101 for Epilepsy Shows Promise at AES Annual Meeting

Lipocine Inc. announced that two abstracts related to LPCN 2101, a potential epilepsy treatment, have been accepted for poster presentation at the 2025 American Epilepsy Society annual meeting. LPCN 2101 is in development for the treatment of epilepsy and has shown promise in clinical trials. The presentation will cover the oral toxicokinetics and clinical pharmacokinetics of the medication, as well as its tolerability. The meeting will be held in Atlanta, Georgia, from December 5-9.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company specializing in innovative oral delivery technologies, has announced that two abstracts related to its epilepsy treatment candidate, LPCN 2101, have been accepted for poster presentation at the 2025 American Epilepsy Society (AES) annual meeting. The meeting will be held in Atlanta, Georgia, from December 5 to December 9 [1].

The abstracts, titled "Oral Toxicokinetics of a Bioidentical GABAA Receptor Modulating Neuroactive Steroid (NAS) Anti-seizure Medication (ASM) Candidate for Women with Epilepsy (WWE)" and "Clinical Pharmacokinetics (PK) and Tolerability of a Novel Oral GABAA Receptor Positive Allosteric Modulating (PAM) Candidate for Epilepsy," will be presented by a team of researchers [1].

LPCN 2101 is in development for the potential treatment of epilepsy and has shown promise in clinical trials. The presentations will cover the oral toxicokinetics and clinical pharmacokinetics of the medication, as well as its tolerability. The abstracts are embargoed from the AES online abstract database until Monday, November 24, 2025 [1].

Lipocine's proprietary technology platform enables the development of products with effective oral delivery, targeting large addressable markets with significant unmet medical needs. The company's clinical development candidates include LPCN 1154, oral brexanolone for postpartum depression, LPCN 2101 for epilepsy, and LPCN 2203 for essential tremor, among others [1].

Eli Lilly, a competitor in the oral GLP-1 pill market, has also recently announced promising data from its Phase 3 trial for an oral GLP-1 pill, which could help people with obesity and Type 2 diabetes lose significant weight [2].

References:
[1] https://www.marketscreener.com/news/lipocine-announces-lpcn-2101-abstracts-accepted-for-presentation-at-aes-2025-ce7c50d9d880f022
[2] https://abcnews.go.com/GMA/Wellness/eli-lillys-oral-glp-1-pill-people-type/story?id=124963525